A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

NCT04980391 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
384
Enrollment
INDUSTRY
Sponsor class

Stopped Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study.

Conditions

Interventions

Sponsor

GlaxoSmithKline